David O’Toole has more than 30 years of experience in the accounting and finance sectors, with emphasis on mergers & acquisitions, fundraising, SEC reporting, and operational excellence. For the past 17 years, his industry focus has been on medical devices, diagnostics, and therapeutics. Prior to Opiant, he was Senior Vice President and Chief Financial Officer at Soleno Therapeutics, Inc., a company that he took public in November of 2014 and raised in excess of $40 million from numerous financing transactions. He was also Senior Vice President and Chief Financial Officer at Codexis, Inc. (2012-2014), a public company focused on developing biocatalysts, Response Genetics, Inc., (2011-2012), a public company focused on cancer diagnostics and was Executive Vice President and Chief Financial Officer of Abraxis Bioscience, Inc. (2008-2010), a public company focused on cancer therapeutics.
David began his career in public accounting with 8 years at Arthur Andersen and then 16 years at Deloitte & Touche LLP, where he served for 12 of those years as a partner. He has a Bachelor of Science degree in accounting from the University of Arizona and is a certified public accountant.